Glymphatic-System Function Is Associated with Addiction and Relapse in Heroin Dependents Undergoing Methadone Maintenance Treatment.

Lei Wang, Yue Qin, Xiaoshi Li, Xin Li, Yuwei Liu, Wei Li, Yarong Wang
Author Information
  1. Lei Wang: Department of Radiology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China. ORCID
  2. Yue Qin: Department of Radiology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
  3. Xiaoshi Li: Department of Radiology, Xi'an Daxing Hospital, Xi'an 710016, China.
  4. Xin Li: Department of Radiology, Xi'an Daxing Hospital, Xi'an 710016, China.
  5. Yuwei Liu: Department of Medical Imaging, People's Hospital of Tongchuan City, Tongchuan 727000, China.
  6. Wei Li: Department of Radiology, Tangdu Hospital, Air Force Military Medical University, Xi'an 710038, China.
  7. Yarong Wang: Department of Radiology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.

Abstract

This study investigates the impact of methadone maintenance treatment (MMT) on the brain glymphatic system (GS) in opioid addiction in China. A total of 51 male MMT patients, 48 demographically matched healthy controls (HCs), and 20 heroin dependents (HDs) were recruited for this study. The GS functioning was assessed using diffusion-tensor-imaging analysis along perivascular spaces (DTI-ALPS index) and the bilateral ALPS divergency (DivALPS). Group differences were analyzed utilizing ANOVA and two-sample -tests. The relationship between DivALPS and relapse rate was explored using regression analysis. The DTI-ALPS index was significantly higher for the left-side brain than the right side in all three groups. There was a significant difference for the right side ( = 0.0098) between the groups. The MMT and HD groups showed significantly higher DTI-ALPS than the HC group ( = 0.018 and 0.016, respectively). The DivALPS varied significantly among the three groups ( = 0.04), with the HD group showing the lowest and the HC group the highest values. Significant negative relationships were found between relapse count, DivALPS ( < 0.0001, Exp(B) = 0.6047), and age ( < 0.0001, Exp(B) = 0.9142). The findings suggest that MMT may contribute to promoting brain GS recovery in heroin addicts, and modulation of the GS may serve as a potential biomarker for relapse risk, providing insights into novel therapeutic strategies.

Keywords

References

  1. BMC Med Res Methodol. 2018 Jun 22;18(1):63 [PMID: 29929477]
  2. Circulation. 2021 Sep 28;144(13):e218-e232 [PMID: 34407637]
  3. Neuroimage. 2019 Jan 15;185:263-273 [PMID: 30342236]
  4. Neurology. 2022 Dec 12;99(24):e2648-e2660 [PMID: 36123122]
  5. Science. 2020 Oct 2;370(6512):50-56 [PMID: 33004510]
  6. Front Public Health. 2019 Nov 12;7:327 [PMID: 31781529]
  7. Addict Behav. 2014 Jan;39(1):22-9 [PMID: 24090627]
  8. Neurobiol Dis. 2018 Apr;112:63-78 [PMID: 29331263]
  9. Sci Pract Perspect. 2002 Jul;1(1):13-20 [PMID: 18567959]
  10. Neuropharmacology. 2022 May 1;208:108986 [PMID: 35134442]
  11. Cell Mol Immunol. 2021 Nov;18(11):2489-2501 [PMID: 34594000]
  12. Nat Neurosci. 2018 Oct;21(10):1380-1391 [PMID: 30224810]
  13. Front Aging Neurosci. 2022 Mar 10;14:841798 [PMID: 35360203]
  14. Front Aging Neurosci. 2021 Jul 19;13:693787 [PMID: 34349635]
  15. J Addict Med. 2013 Sep-Oct;7(5):342-8 [PMID: 23896752]
  16. Curr Neuropharmacol. 2017 Nov 14;15(8):1156-1173 [PMID: 28474563]
  17. J Neurosci. 2013 Nov 13;33(46):18190-9 [PMID: 24227727]
  18. Drug Alcohol Depend. 2018 Oct 1;191:1-5 [PMID: 30064001]
  19. Neuroscience. 2021 Oct 15;474:63-79 [PMID: 33248153]
  20. Front Physiol. 2016 Oct 13;7:436 [PMID: 27790151]
  21. Eur Radiol. 2023 Sep;33(9):6116-6123 [PMID: 37010581]
  22. P T. 2011 Aug;36(8):462-6 [PMID: 21935293]
  23. Jpn J Radiol. 2022 Feb;40(2):147-158 [PMID: 34390452]
  24. Cochrane Database Syst Rev. 2002;(4):CD002209 [PMID: 12519570]
  25. Brain Behav Immun. 2010 Jan;24(1):83-95 [PMID: 19679181]
  26. BMC Med Res Methodol. 2014 Jun 26;14:82 [PMID: 24965498]
  27. Clin J Pain. 2002 Jul-Aug;18(4 Suppl):S14-27 [PMID: 12479251]
  28. Sci Transl Med. 2012 Aug 15;4(147):147ra111 [PMID: 22896675]
  29. J Neurosci. 2021 Sep 15;41(37):7698-7711 [PMID: 34526407]
  30. Brain Behav Immun. 2020 Mar;85:106-119 [PMID: 31247290]
  31. Addict Biol. 2017 Jul;22(4):1068-1080 [PMID: 26987308]
  32. Neuroimage. 2021 Sep;238:118257 [PMID: 34118396]
  33. Acad Forensic Pathol. 2017 Mar;7(1):91-98 [PMID: 31239961]
  34. Expert Opin Pharmacother. 2016 Dec;17(17):2307-2318 [PMID: 27734745]
  35. NPJ Parkinsons Dis. 2022 Dec 21;8(1):174 [PMID: 36543809]
  36. Neuroimage. 2012 Aug 15;62(2):782-90 [PMID: 21979382]
  37. Drug Alcohol Depend. 2019 Jan 1;194:143-150 [PMID: 30445272]
  38. Front Hum Neurosci. 2020 Aug 13;14:300 [PMID: 32922272]
  39. J Med Case Rep. 2013 Feb 21;7:51 [PMID: 23432798]
  40. Psychol Med. 2023 Apr;53(6):2216-2228 [PMID: 34702384]
  41. Psychiatry Res. 2015 Mar 30;226(1):230-4 [PMID: 25660662]
  42. Jpn J Radiol. 2017 Apr;35(4):172-178 [PMID: 28197821]
  43. Brain Behav Immun. 2020 Aug;88:97-104 [PMID: 32335199]
  44. Lab Invest. 2006 Jan;86(1):9-22 [PMID: 16357866]
  45. Brain Behav. 2016 Jan 24;6(2):e00436 [PMID: 27110449]
  46. Sci Rep. 2015 Oct 15;5:15181 [PMID: 26469876]
  47. Neuroimage. 2022 Nov 15;262:119534 [PMID: 35931311]
  48. Front Neurosci. 2023 Mar 31;17:1132393 [PMID: 37065921]
  49. Oxid Med Cell Longev. 2022 Jul 5;2022:2694316 [PMID: 35847591]
  50. J Neuroimmunol. 2013 Feb 15;255(1-2):39-44 [PMID: 23177720]
  51. Exp Clin Psychopharmacol. 2014 Jun;22(3):248-256 [PMID: 24548244]
  52. Postgrad Med J. 2004 Nov;80(949):654-9 [PMID: 15537850]
  53. Pharmacol Res. 2004 Dec;50(6):551-9 [PMID: 15501692]
  54. Brain Commun. 2021 Sep 06;3(3):fcab211 [PMID: 34557668]
  55. Nat Rev Drug Discov. 2022 Oct;21(10):763-779 [PMID: 35948785]
  56. Transl Psychiatry. 2023 Apr 8;13(1):120 [PMID: 37031205]
  57. J Neurosci. 2012 Aug 15;32(33):11187-200 [PMID: 22895704]
  58. Neuroimage. 2023 Jul 1;274:120124 [PMID: 37084927]
  59. Brain Behav Immun. 2008 Jan;22(1):114-23 [PMID: 17919885]
  60. J Psychiatry Neurosci. 2018 Jan;43(1):48-57 [PMID: 29252165]
  61. Glob J Health Sci. 2014 Sep 18;6(7 Spec No):83-91 [PMID: 25363183]
  62. J Exp Med. 2015 Jun 29;212(7):991-9 [PMID: 26077718]

Grants

  1. 82071497;81771813/National Natural Science Foundation of China

Word Cloud

Created with Highcharts 10.0.00MMT=GSDTI-ALPSDivALPSgroupsbrainheroinrelapsesignificantlygroupstudymethadonemaintenancetreatmentglymphaticsystemusinganalysisindexhigherrightsidethreeHDHC<0001ExpBmayinvestigatesimpactopioidaddictionChinatotal51malepatients48demographicallymatchedhealthycontrolsHCs20dependentsHDsrecruitedfunctioningassesseddiffusion-tensor-imagingalongperivascularspacesbilateralALPSdivergencyGroupdifferencesanalyzedutilizingANOVAtwo-sample-testsrelationshiprateexploredregressionleft-sidesignificantdifference0098showed018016respectivelyvariedamong04showinglowesthighestvaluesSignificantnegativerelationshipsfoundcount6047age9142findingssuggestcontributepromotingrecoveryaddictsmodulationservepotentialbiomarkerriskprovidinginsightsnoveltherapeuticstrategiesGlymphatic-SystemFunctionAssociatedAddictionRelapseHeroinDependentsUndergoingMethadoneMaintenanceTreatmentdependence

Similar Articles

Cited By